GlycoNex

GlycoNex Net Margin

The Net Profit Margin of GlycoNex (4168.TWO) as of Nov 4, 2026 is -621.29 %. In the previous year, Net Profit Margin was -1,562.51 % — a change of -60.24% (higher).

Net Margin

-621.29 %

YoY

-60.24%

Last updated:

Net Profit Margin of GlycoNex is 2025 -621.29 % . Net Profit Margin of GlycoNex was 2024 -1,562.51 % . It decreases by -60.24% higher compared to the previous year.

GlycoNex's net margin stands at -621.3%, up from -3,150.6% several years earlier.

The GlycoNex Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-34,227.11 TWD
Jan 1, 2019
-33,682.15 TWD
Jan 1, 2020
-36,082.26 TWD
Jan 1, 2021
-3,150.56 TWD
Jan 1, 2022
-730.67 TWD
Jan 1, 2023
-7,016.60 TWD
Jan 1, 2024
-1,562.51 TWD
Jan 1, 2025
-621.29 TWD
The GlycoNex Net Margin history
YEARNet MarginYoY
-621.29 %-60.24%
-1,562.51 %-77.73%
-7,016.60 %+860.30%
-730.67 %-76.81%
-3,150.56 %-91.27%
-36,082.26 %+7.13%
-33,682.15 %-1.59%
-34,227.11 %+50.08%
-22,805.68 %-44.04%
-40,752.72 %+3,579.56%
-1,107.54 %+110.85%
-525.26 %+87,373.69%
-0.60 %-424.04%
0.19 %-24.81%
0.25 %-104.75%
-5.19 %-1,260.84%
0.45 %-113.63%
-3.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GlycoNex Stock analysis

What does GlycoNex do? GlycoNex, Inc. develops anti-cancer monoclonal antibodies and bio-similar drugs, offering licensing for monoclonal antibody targets and carbohydrate antigen and protein drug services. The company targets domestic and Asian markets, distributing its products through these regions. Revenue comes from drug development, licensing agreements, and service provision for antibody targets and related biotech solutions. GlycoNex focuses on anti-cancer monoclonal antibody new drugs and bio-similar drugs, with services including carbohydrate antigen and protein drug related offerings. The firm serves domestic and overseas markets in Asia, generating income from product development, licensing, and specialized biotech services. Its business model relies on developing and commercializing innovative cancer treatments and related services in key Asian markets. The company's revenue streams include the development of anti-cancer monoclonal antibody new drugs, bio-similar drugs, and the licensing of monoclonal antibody targets. Services related to carbohydrate antigen and protein drug solutions are also part of the business, distributed across domestic and Asian markets to generate income from pharmaceutical innovation and biotech service contracts. GlycoNex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GlycoNex stock

Net Profit Margin of GlycoNex is -621.29 % in 2025.

Net Profit Margin of GlycoNex changed from -1,562.51 % to -621.29 %, representing a -60.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin GlycoNex since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's GlycoNex with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — GlycoNex

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — GlycoNex